p53/p21 Pathway Involved in Mediating Cellular Senescence of Bone Marrow-Derived Mesenchymal Stem Cells from Systemic Lupus Erythematosus Patients

Table 1

Clinical features of 22 SLE Patients.

Patients	Age (years) and sex	Disease duration	Current treated	SLEDAI
1	19 F	2 y	Pred: 20–40 mg/day; CTX: 0.4 g/2 weeks; HCQ: 0.2/day; MMF: 1.5–2.0 g/day	30
2	22 F	1.5 y	Pred: 15–20 mg/day; CTX: 0.4 g/2 weeks; HCQ: 0.2/day	24
3	39 F	10 y	Pred: 10 mg/day; HCQ: 0.2/day	8
4	37 F	8 y	Pred: 15–20 mg/day; LEF: 0.2 g/day; HCQ: 0.2/day	22
5	24 F	1 y	Pred: 15 mg/day	8
6	42 F	6 y	Pred: 20–30 mg/day; HCQ: 0.4/day; CTX: 0.6 g/3 weeks	26
7	28 F	1 y	Pred: 10 mg/day; HCQ: 0.2/day	12
8	23 F	1 y	Pred: 5–7.5 mg/day; HCQ: 0.2/day; CTX: 0.4 g/4 weeks	18
9	32 F	3 y	Pred: 5–10 mg/day; LEF: 0.2 g/day; HCQ: 0.2/day	12
10	25 F	4 y	Pred: 5–7.5 mg/day; LEF: 0.2 g/day; HCQ: 0.2/day	16
11	14 F	2 y	Pred: 5–10 mg/day; HCQ: 0.2/day; MMF: 1.5–2.0 g/day	9
12	21 F	2 m	Pred: 7.5–10 mg/day; MMF: 1.5–2.0 g/day; HCQ: 0.2/day	19
13	32 F	4 m	Pred: 5–7.5 mg/day; LEF: 0.2 g/day; HCQ: 0.2/day	16
14	20 F	7 m	Pred: 10–15 mg/day; LEF: 0.2 g/day; HCQ: 0.2/day	21
15	24 F	2 m	Pred: 7.5–10 mg/day; LEF: 0.2 g/day; HCQ: 0.2/day	18
16	22 F	3 m	Pred: 30–40 mg/day; MMF: 1.5–2.0 g/day; HCQ: 0.4/day	26
17	15 F	1 m	Pred: 5 mg/day; HCQ: 0.2/day	8
18	33 F	4 m	Pred: 5–7.5 mg/day; LEF: 0.2 g/day; HCQ: 0.2/day	12
19	36 F	3 m	Pred: 7.5 mg/day; HCQ: 0.2/day	9
20	23 F	8 m	Pred: 20–40 mg/day; CTX: 0.4 g/2 weeks; HCQ: 0.2/day	17
21	20 F	4 m	Pred: 20–30 mg/day; CTX: 0.4 g/4 weeks; HCQ: 0.2/day	14
22	29 F	6 m	Pred: 20–40 mg/day; CTX: 0.4 g/2 weeks; HCQ: 0.2/day	20

y: years; m: mouth; S: skin; J: joints; H: hematologic; M: myositis; V: vasculitis; R: renal; Pred: prednisolone; HCQ: hydroxychloroquine; CTX: cyclophosphamide; LEF: Leflunomide; MMF: Mycophenolate Mofetil.